C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 471/04 (2006.01) A61K 31/437 (2006.01) A61K 31/4545 (2006.01) A61P 3/00 (2006.01)
Patent
CA 2693214
Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treat-ment of depression and anxiety.
L'invention concerne des dérivés de bêta-carboline, de la formule structurelle I, qui sont des antagonistes sélectifs du récepteur 3 du sous-type somatostatine (SSTR3) et qui s'utilisent pour le traitement du diabète Mellitus de type 2 et des états qui sont souvent associés à cette maladie, y compris l'hyperglycémie, la résistance à l'insuline, l'obésité, les troubles lipidiques et l'hypertension. Les composés s'utilisent également pour le traitement de la dépression et de l'anxiété.
Bakshi Raman
Dellureficio James
Dobbelaar Peter H.
Du Wu
Guo Liangqin
Gowling Lafleur Henderson Llp
Merck Sharp & Dohme Corp.
LandOfFree
Beta carboline derivatives as antidiabetic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Beta carboline derivatives as antidiabetic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beta carboline derivatives as antidiabetic compounds will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1965448